Latest Biotech News

Braveheart Bio priced a $382 million IPO, with underwriters exercising an option to purchase more shares and pushing the company’s total proceeds to nearly $440 million. The clinical-stage firm’s...

Latigo Biotherapeutics launched an IPO that brought in $346 million earmarked for a non-opioid pain program progressing toward pivotal testing. The company also plans to allocate proceeds to...

A study overturning long-held views from mouse work reports that bone marrow-derived cells infiltrate the aging human brain and replenish microglia. The finding reframes what drives microglial...

Researchers report engineered nanovesicles that target METTL3, the m6A writer, to curb neuroinflammation in both cell and animal models. The work, published in Nature Communications, describes a...

A new experimental cancer approach combines bacterial tumor targeting with nutrient deprivation and immune stimulation in a single engineered therapeutic. In work published in Nature...

A new deep-learning framework called MRICombo unifies multiple MRI oncology tasks into a single model for tumor segmentation, grading, staging, and malignancy detection. The system, described in...

Yale University neuroscientist Daniel Colón-Ramos continues a long-running effort to dissect the molecular requirements for synapse formation using the transparent nematode Caenorhabditis elegans....

A British Journal of Cancer study examines how neuroblastoma balances replication stress with genome stability across chromosome 17q. The paper focuses on how this balance may help explain why...

Researchers mapped signaling networks driving disseminated glioblastoma cells in living brains in a Nature Communications study led by Ahn, D’Souza, Long and colleagues. The approach targets a...

A Nature Communications study reports that a short-term restriction of animal products rapidly alters human proteogenomic profiles. Researchers including A. Simistiras, O. Bocher, C. Emmanouil and...

Bipartisan lawmakers moved to restrain HHS’ 340B rebate push, introducing a bill that would lock in hospitals’ use of contract pharmacies while adding transparency and compliance requirements. The...

FDA granted accelerated approval to Replimune’s oncolytic viral therapy Tudriqev for advanced melanoma, after the program previously faced twice-spurned FDA feedback. The approval followed a...

BioCentury reported that FDA regulatory moves reflect a steadying approach amid earlier controversy, with therapies from Moderna and Replimune emerging from disputes to receive approvals alongside...

Otsuka’s Voyxact (anti-APRIL) advanced IgA nephropathy expectations with Phase III eGFR-slope results suggesting the drug may halt or reverse kidney function decline. The data were highlighted as...

A new Nature Communications study introduced MRICombo, a deep-learning framework designed to unify MRI tumor workflows including segmentation, grading, staging, and malignancy detection. The aim...

Rice University engineers reported a charge-based strategy to improve controlled delivery of therapeutic peptides released from gelatin-based materials. By tuning how peptides are presented and...

In Nature Communications, Weidle, Brunette, Wrenn and colleagues reported a pan-Ebolavirus nanoparticle vaccine that protected rodents against lethal infections from both Zaire and Sudan virus...

A study highlighted a biomarker interaction that may predict breast cancer spread and treatment benefit, focusing on why patients with similar profiles can experience very different outcomes....

Nature Communications reported that short-term restriction of animal products rapidly alters human proteogenomic profiles at the molecular level. The study by A. Simistiras, O. Bocher, C....

A Nature Communications study described engineered nanovesicles that target the m6A writer METTL3 to curb neuroinflammation in cell and animal models. The work from Xu, Pan, Li and colleagues...